Attenuates Carotid Artery Intimal Hyperplasia and Increases Endothelial Progenitor Cell Activity Via the PI3K/Akt Signalling Pathway in Wire-injured Rats
Overview
Affiliations
Context: Clinically, (Thunb.) Breit. (Araceae) () has been widely used in the treatment of atherosclerosis and hyperlipidaemia, but the underlying mechanisms are still not clearly understood.
Objective: This research was conducted to confirm the mechanism by which affects carotid artery intimal hyperplasia.
Materials And Methods: An intestinal hyperplasia Sprague-Dawley rat model was established by carotid artery injury. The rats were randomly divided into five groups ( = 8): sham, model, (with daily intragastric administration of 10 g/mL/kg tubers water extract), +LY294002 (with intraperitoneal injection of 50 mg/kg LY294002 + 10 g/mL/kg ) and endothelial progenitor cells (EPCs) (with injection of 5 × 10/cells), and treated for 4 or 8 weeks.
Results: HE staining showed that attenuated intimal hyperplasia. RT-PCR, Western blotting and immunohistochemistry showed that increased the expression of vascular endothelial growth factor (VEGF) and eNOS in the atherosclerotic carotid artery. increased the Dil-acLDL/FITC-UEA-1 population (from 0.41 ± 0.085% to 0.60 ± 0.092%) in the blood, decreased TCHO, TG, LDL-C, IL-6 and TNF-α levels, and increased HDL-C and IL-10 levels in the blood. However, these changes were reversed by the PI3K/Akt pathway inhibitor LY294002.
Discussion And Conclusions: can be developed as an atherosclerosis and carotid intimal hyperplasia treatment drug. Therefore, further study will focus on the effects of on intimal hyperplasia in wire-injured atherosclerosis patients and explore in depth some other relevant molecular mechanisms.
A review on the treatment of hyperlipidemia with Erchen Decoction.
Tian X, Liu P, Wang R, Hou Y, Zhou Y, Wang C Front Pharmacol. 2024; 15:1445950.
PMID: 39605912 PMC: 11598526. DOI: 10.3389/fphar.2024.1445950.
Liu Y, Bai Y, Zhang J, Silva-Filho R, Zhu Q, Lei Z J Gastrointest Oncol. 2023; 14(5):2006-2017.
PMID: 37969842 PMC: 10643601. DOI: 10.21037/jgo-23-684.
Shao X, Liu Y, Jiang C, Sun Y, Zhang Q, Gu J Evid Based Complement Alternat Med. 2022; 2022:2662288.
PMID: 35547655 PMC: 9085321. DOI: 10.1155/2022/2662288.